Weqar Naser Naser

Dr. Weqar Naser Naser

orcid

Research Focus & Metrics

Representative Publications

View All Publications
5 November 2026 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
AHAli Mohammad Hussein
Ali Mohammad Hussein
SKSalman Kaladari
Salman Kaladari
WNWeqar Naser Naser
Weqar Naser Naser
AAAysha Albusaiteeni
Aysha Albusaiteeni
NKNader Khawaja
Nader Khawaja
FAFaisal Osman Abdelaziz Abubaker
Faisal Osman Abdelaziz Abubaker
Background: Biologic and small-molecule therapies have transformed inflammatory bowel disease (IBD) management, yet real-world evidence from the Gulf region remains limited. This study evaluated 12-month clinical, biochemical, and endoscopic outcomes among adults with moderate-to-severe Crohn’s disease (CD) or ulcerative colitis (UC) receiving advanced therapy in Bahrain. Material and Methods: This retrospective observational cohort included 122 patients who remained on the same biologic or small-molecule therapy for 12 months and underwent baseline and follow-up endoscopy. The primary outcome was clinical remission; secondary outcomes included corticosteroid-free status, endoscopic outcomes, IBD-related hospitalization and surgery, and biochemical changes. Results: Of the 122 patients, 95 (77.9%) had CD and 27 (22.1%) had UC. At 12 months, 49.2% achieved clinical remission, 60.7% were corticosteroid-free, and endoscopic response and remission were achieved in 62.3% and 49.2%, respectively. Significant improvements were observed in C-reactive protein, serum albumin, and fecal calprotectin (all p < 0.001). In exploratory, unadjusted analyses, clinical remission and corticosteroid-free status were more frequent with anti-TNF than with non-anti-TNF therapy, whereas endoscopic outcomes did not differ significantly. IBD-related hospitalization (40.2%) and surgery (28.7%) remained substantial. Conclusions: Among patients with moderate-to-severe IBD who remained on biologic or small-molecule therapy for 12 months, treatment was associated with meaningful clinical, biochemical, and endoscopic improvement. However, hospitalization and surgery remained substantial, and the treatment-completer design may have overestimated effectiveness relative to the broader population initiating therapy. These findings add real-world evidence from Bahrain and support larger prospective, multicenter studies with standardized outcomes and longer follow-up.